Compare · ELV vs MDXH
ELV vs MDXH
Side-by-side comparison of Elevance Health Inc. (ELV) and MDxHealth SA (MDXH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and MDXH operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $90.81B, about 3237.9x MDXH ($28.0M).
- Over the past year, ELV is up 7.7% and MDXH is down 73.2% - ELV leads by 80.9 points.
- MDXH has been more active in the news (10 items in the past 4 weeks vs 3 for ELV).
- ELV has more recent analyst coverage (23 ratings vs 5 for MDXH).
- Company
- Elevance Health Inc.
- MDxHealth SA
- Price
- $419.74+0.34%
- $0.59+7.14%
- Market cap
- $90.81B
- $28.0M
- 1M return
- +11.15%
- -70.65%
- 1Y return
- +7.72%
- -73.18%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 3
- 10
- Recent ratings
- 23
- 5
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
MDxHealth SA
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Latest ELV
- Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide
- CAO & Controller Penczek Ronald W exercised 1,531 shares at a strike of $294.30 and sold $617,192 worth of shares (1,531 units at $403.13) (SEC Form 4)
- Elevance Health upgraded by Deutsche Bank with a new price target
- Director Schulman Amy W was granted 563 shares, increasing direct ownership by 258% to 781 units (SEC Form 4)
- Director Schneider Ryan M. was granted 563 shares, increasing direct ownership by 9% to 7,163 units (SEC Form 4)
- Director Peru Ramiro G was granted 563 shares, increasing direct ownership by 6% to 9,908 units (SEC Form 4)
- Director Neri Antonio F was granted 563 shares, increasing direct ownership by 11% to 5,488 units (SEC Form 4)
- Director Jallal Bahija was granted 563 shares, increasing direct ownership by 12% to 5,351 units (SEC Form 4)
- Director Hay Lewis Iii was granted 563 shares, increasing direct ownership by 5% to 12,070 units (SEC Form 4)
- Director Dixon Robert L Jr was granted 563 shares, increasing direct ownership by 5% to 10,885 units (SEC Form 4)
Latest MDXH
- SEC Form 4 filed by Officer Sollee Joseph
- SEC Form 4 filed by Director Hardison Don M
- SEC Form 4 filed by Chief Executive Officer Mcgarrity Michael
- SEC Form 4 filed by VP, Finance and Accounting Oconnell Brendan
- SEC Form 4 filed by Director Hoffman Koen
- SEC Form 4 filed by Chief Commercial Officer Bellano John
- SEC Form 4 filed by Director Siegel Sanford Jay
- SEC Form 4 filed by Director Windels Hilde
- SEC Form 4 filed by Director Holder Michael
- SEC Form 3 filed by new insider Oconnell Brendan